<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024010</url>
  </required_header>
  <id_info>
    <org_study_id>MC0983</org_study_id>
    <secondary_id>NCI-2009-01437</secondary_id>
    <secondary_id>MC0983</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT01024010</nct_id>
  </id_info>
  <brief_title>Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</brief_title>
  <official_title>Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving ofatumumab together with pentostatin and
      cyclophosphamide works in treating patients with untreated chronic lymphocytic leukemia or
      small lymphocytic lymphoma. Monoclonal antibodies, such as ofatumumab, can block the ability
      of cancer cells to grow and spread. Drugs used in chemotherapy, such as pentostatin and
      cyclophosphamide, work in different ways to stop the growth of cancer cells, either by
      killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
      ofatumumab together with pentostatin and cyclophosphamide may be a better way to block cancer
      growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Arm A: To assess the rate of complete response using pentostatin, cyclophosphamide, and
      ofatumumab in patients with previously untreated chronic lymphocytic leukemia (CLL) or small
      lymphocytic lymphoma (SLL) requiring therapy.

      II. Arm B: To assess the treatment-free survival rate at 18 months using pentostatin,
      cyclophosphamide, and ofatumumab induction therapy followed by ofatumumab consolidation in
      patients with previously untreated CLL or SLL requiring therapy.

      SECONDARY OBJECTIVES:

      I. Arm A and Arm B: To assess the rate of overall response in patients with previously
      untreated CLL or SLL requiring therapy and to determine the proportion of patients who
      achieve a minimal residual disease (MRD) negative state as assessed by flow cytometry in each
      arm independently.

      II. Arm A and Arm B: To monitor and assess toxicity in patients with previously untreated CLL
      or SLL in each arm independently.

      III. Arm A and Arm B: To determine the progression-free survival, treatment-free survival,
      and duration of response in each arm independently.

      IV. Arm A and Arm B: To determine if molecular prognostic parameters (zeta-chain-associated
      protein [ZAP]-70, cluster of differentiation [CD]38, cytogenetic abnormalities identified by
      fluorescence in situ hybridization [FISH], immunoglobulin heavy-chain variable-region [IgVH]
      mutation status, etc) relate to response to therapy in each arm independently.

      V. Arm B: To assess the rate of complete response using pentostatin, cyclophosphamide, and
      ofatumumab induction followed by ofatumumab consolidation in patients with previously
      untreated CLL or SLL requiring therapy.

      VI. Arm B: To evaluate whether consolidation therapy with ofatumumab after pentostatin,
      cyclophosphamide, and ofatumumab (PCO) induction improves the depth of response.

      TERTIARY OBJECTIVES:

      I. Arm A and Arm B: To assess the complete and overall response as well as treatment free
      survival in each arm as compared to a historic control of patients treated with pentostatin,
      cyclophosphamide, and rituximab in an exploratory manner.

      II. Arm A and Arm B: To assess the complete and overall response as well as treatment free
      survival of patients treated with PCO induction followed by ofatumumab consolidation (Arm B)
      as compared to patients treated with PCO induction who did not receive ofatumumab
      consolidation (Arm A) in an exploratory manner.

      III. Arm A and Arm B: Assess the mechanisms of ofatumumab induced cell death and explore
      methods to enhance ofatumumab cytotoxicity.

      OUTLINE: Patients are assigned to 1 of 2 treatment arms.

      ARM A (closed to accrual as of 8/23/2011): Patients receive induction therapy comprising
      ofatumumab intravenously (IV) on day 1 (days 1-2 of course 1 only), pentostatin IV over 30
      minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every
      21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

      ARM B: Patients receive induction therapy as in Arm A. Patients then receive consolidation
      therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in
      the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 90 days for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2010</start_date>
  <completion_date type="Actual">September 28, 2017</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm A: Percentage of Complete Responses</measure>
    <time_frame>7 months</time_frame>
    <description>In Arm A: PCO, the primary endpoint of this trial is the percentage of complete responses. The NCI Working Group criteria was used to assess response to therapy:
A Complete Response (CR) is briefly defines as the absence of lymphadenopathy, no heptomegaly nor splenomegaly, neutrophils greater than 1500/ul, platelets &gt; 100,000/ul, hemoglobin &gt;11.0 gm/dl, and peripheral blood lymphocytes &lt;4000uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm B: Treatment-free Survival at 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>The primary endpoint Arm B: PCO+O is treatment-free survival rate at 18 months. An event for treatment-free survival will be defined as initiation of subsequent therapy for CLL or death due to any cause. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for event-free survival at 18 months. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>14 months</time_frame>
    <description>The overall response rate will be estimated by the total number of complete or partial responses (CCR, CR, CRi, nPR, or PR) divided by the total number of evaluable patients. Responses will be evaluated using NCI Working Group criteria. Minimum requirements for a Partial Response (PR) requires:
50% decrease in peripheral blood lymphocyte count from the baseline
50% reduction in the sum of the products of the largest measured node or nodal masses on physical examination.
50% reduction in size of liver and/or spleen
50% improvement in neutrophils, platelets and hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of Response After Ofatumumab Consolidation</measure>
    <time_frame>14 months</time_frame>
    <description>The proportion of patients with an improvement in depth of response with the addition of ofatumumab consolidation after PCO induction will be estimated by the number of patients with improvement in response from the time of response evaluation at the completion of PCO to the time of response evaluation at the completion of ofatumumab consolidation divided by the total number of evaluable patients. The hierarchy for depth of response will be in the following increasing order: SD, PR, nPR, CR/CRi with MRD+, CR/CRi with MRD-. An improvement in depth of response will be defined as an improvement of at least one level in the hierarchy. Exact binomial 95% confidence intervals for the true overall improvement rate will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-free Survival</measure>
    <time_frame>up to 5 years from registration</time_frame>
    <description>Treatment-free survial is defined as the time from registration to the date of initiation of subsequent treatment for CLL or death due to any cause. The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Stage 0 Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Small Lymphocytic Lymphoma</condition>
  <condition>Stage II Chronic Lymphocytic Leukemia</condition>
  <condition>Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Small Lymphocytic Lymphoma</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (PCO, closed to accrual as of 8/23/2011)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (PCO with ofatumumab consolidation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (PCO, closed to accrual as of 8/23/2011)</arm_group_label>
    <arm_group_label>Arm B (PCO with ofatumumab consolidation)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (PCO, closed to accrual as of 8/23/2011)</arm_group_label>
    <arm_group_label>Arm B (PCO with ofatumumab consolidation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (PCO, closed to accrual as of 8/23/2011)</arm_group_label>
    <arm_group_label>Arm B (PCO with ofatumumab consolidation)</arm_group_label>
    <other_name>Arzerra</other_name>
    <other_name>GSK1841157</other_name>
    <other_name>HuMax-CD20</other_name>
    <other_name>HuMax-CD20, 2F2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentostatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (PCO, closed to accrual as of 8/23/2011)</arm_group_label>
    <arm_group_label>Arm B (PCO with ofatumumab consolidation)</arm_group_label>
    <other_name>(R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7, 8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol</other_name>
    <other_name>2'-Deoxycoformycin</other_name>
    <other_name>CI-825</other_name>
    <other_name>Co-Vidarabine</other_name>
    <other_name>Covidarabine</other_name>
    <other_name>DCF</other_name>
    <other_name>Deoxycoformycin</other_name>
    <other_name>Nipent</other_name>
    <other_name>PD-81565</other_name>
    <other_name>Pentostatine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CLL according to the National Cancer Institute (NCI) criteria or SLL
             according to the World Health Organization (WHO) criteria, including previous
             documentation of:

          -  Biopsy-proven SLL

          -  Diagnosis of CLL according to NCI working group criteria as evidenced by all of the
             following:

               -  Peripheral blood lymphocyte count of &gt; 5,000/mm^3 consisting of small to moderate
                  size lymphocytes, with &lt; 55% prolymphocytes

               -  Immunophenotyping consistent with CLL defined as:

                    -  The predominant population of lymphocytes share both B-cell antigens (CD19,
                       CD20 [typically dim expression], or CD23) as well as CD5 in the absence of
                       other pan-T-cell markers (CD3, CD2, etc.)

                    -  Clonality as evidenced by kappa or lambda light chain expression (typically
                       dim immunoglobulin expression)

                    -  Note: splenomegaly, hepatomegaly, or lymphadenopathy are not required for
                       the diagnosis of CLL

               -  Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by
                  demonstrating a negative FISH analysis for t(11;14)(immunoglobulin heavy
                  [IgH]/cyclin D1 [CCND1]) on peripheral blood or tissue biopsy or negative
                  immunohistochemical stains for CCND1 on involved tissue biopsy

          -  Patients must be previously untreated and meet at least one of the following
             indications for chemotherapy:

               -  Evidence of progressive marrow failure as manifested by the development of or
                  worsening anemia (=&lt; 11 g/dl) and/or thrombocytopenia (=&lt; 100,000/mm^3) not due
                  to autoimmune disease

               -  Symptomatic or progressive lymphadenopathy, splenomegaly or hepatomegaly

               -  One or more of the following disease-related symptoms:

                    -  Weight loss &gt; 10% within the previous 6 months

                    -  Extreme fatigue attributed to CLL

                    -  Fevers &gt; 100.5 degree Fahrenheit for 2 weeks without evidence of infection

                    -  Drenching night sweats without evidence of infection

               -  Progressive lymphocytosis due to CLL with an increase of &gt; 50% over a two-month
                  period or an anticipated doubling time of less than six months

                    -  Prior chemotherapy or monoclonal antibody based therapy for treatment of CLL
                       will be considered prior therapy; nutraceutical treatments with no
                       established benefit in CLL (such as epigallocatechin gallate [EGCG], found
                       in green tea or other herbal treatments) will not be considered &quot;prior
                       treatment&quot;

                    -  Marked hypogammaglobulinemia or the development of a monoclonal protein in
                       the absence of any of the above criteria for active disease are not
                       sufficient for protocol therapy

          -  Serum creatinine =&lt; 1.5 x upper normal levels (UNL)

          -  Total bilirubin =&lt; 1.5 x UNL unless due to Gilbert's disease; if total bilirubin is &gt;
             1.5 x UNL, a direct bilirubin should be performed and must be &lt; 1.5 mg/dL for
             Gilbert's to be diagnosed

          -  Aspartate aminotransferase (AST) =&lt; 3.0 x UNL and alanine aminotransferase (ALT) =&lt;
             3.0 x UNL (unless due to hemolysis or CLL)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1, or 2

          -  Willingness to provide blood samples as required

          -  Able to adhere to the study visit schedule and other protocol requirements

        Exclusion Criteria:

          -  Any of the following comorbid conditions:

               -  New York Heart Association Class III or IV heart disease

               -  Recent myocardial infarction (&lt; 1 month)

               -  Uncontrolled infection

               -  Infection with the human immunodeficiency virus (HIV/acquired immunodeficiency
                  syndrome [AIDS])

               -  Infection with known chronic, active Hepatitis C

               -  Positive serology for hepatitis B (HB) defined as a positive test for HB surface
                  antigen (HBsAg); in addition, if negative for HBsAg but HB core antibody (HBcAb)
                  positive (regardless of HBsAb status), a HB deoxyribonucleic acid (DNA) test will
                  be performed and if positive the subject will be excluded

          -  Pregnant women

          -  Nursing women

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception

          -  Other active primary malignancy requiring treatment or limiting survival to =&lt; 2 years

          -  Any radiation therapy =&lt; 4 weeks prior to registration

          -  Any major surgery =&lt; 4 weeks prior to registration

          -  Current use of corticosteroids; EXCEPTION: low doses of steroids (&lt; 10 mg of
             prednisone or equivalent dose of other steroid) used for treatment of non-hematologic
             medical conditions; Note: previous use of corticosteroids is allowed

          -  Active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic
             treatment; patients who have a positive Coombs test but no evidence of hemolysis are
             NOT excluded from participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tait Shanafelt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <results_first_submitted>August 4, 2016</results_first_submitted>
  <results_first_submitted_qc>August 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2018</results_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: PCO</title>
          <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: PCO +O</title>
          <description>Patients receive 300 mg ofatumumab IV on day 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.
For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: PCO</title>
          <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: PCO +O</title>
          <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.
For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="50" upper_limit="83"/>
                    <measurement group_id="B2" value="59" lower_limit="40" upper_limit="79"/>
                    <measurement group_id="B3" value="63" lower_limit="40" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arm A: Percentage of Complete Responses</title>
        <description>In Arm A: PCO, the primary endpoint of this trial is the percentage of complete responses. The NCI Working Group criteria was used to assess response to therapy:
A Complete Response (CR) is briefly defines as the absence of lymphadenopathy, no heptomegaly nor splenomegaly, neutrophils greater than 1500/ul, platelets &gt; 100,000/ul, hemoglobin &gt;11.0 gm/dl, and peripheral blood lymphocytes &lt;4000uL.</description>
        <time_frame>7 months</time_frame>
        <population>All patients that began Arm A protocol treatment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: PCO</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm A: Percentage of Complete Responses</title>
          <description>In Arm A: PCO, the primary endpoint of this trial is the percentage of complete responses. The NCI Working Group criteria was used to assess response to therapy:
A Complete Response (CR) is briefly defines as the absence of lymphadenopathy, no heptomegaly nor splenomegaly, neutrophils greater than 1500/ul, platelets &gt; 100,000/ul, hemoglobin &gt;11.0 gm/dl, and peripheral blood lymphocytes &lt;4000uL.</description>
          <population>All patients that began Arm A protocol treatment were included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="31" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arm B: Treatment-free Survival at 18 Months</title>
        <description>The primary endpoint Arm B: PCO+O is treatment-free survival rate at 18 months. An event for treatment-free survival will be defined as initiation of subsequent therapy for CLL or death due to any cause. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for event-free survival at 18 months. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: PCO</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: PCO +O</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.
For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm B: Treatment-free Survival at 18 Months</title>
          <description>The primary endpoint Arm B: PCO+O is treatment-free survival rate at 18 months. An event for treatment-free survival will be defined as initiation of subsequent therapy for CLL or death due to any cause. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for event-free survival at 18 months. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="74.3" upper_limit="94.2"/>
                    <measurement group_id="O2" value="94.1" lower_limit="78.5" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>The overall response rate will be estimated by the total number of complete or partial responses (CCR, CR, CRi, nPR, or PR) divided by the total number of evaluable patients. Responses will be evaluated using NCI Working Group criteria. Minimum requirements for a Partial Response (PR) requires:
50% decrease in peripheral blood lymphocyte count from the baseline
50% reduction in the sum of the products of the largest measured node or nodal masses on physical examination.
50% reduction in size of liver and/or spleen
50% improvement in neutrophils, platelets and hemoglobin</description>
        <time_frame>14 months</time_frame>
        <population>All patients were evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: PCO</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: PCO +O</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.
For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>The overall response rate will be estimated by the total number of complete or partial responses (CCR, CR, CRi, nPR, or PR) divided by the total number of evaluable patients. Responses will be evaluated using NCI Working Group criteria. Minimum requirements for a Partial Response (PR) requires:
50% decrease in peripheral blood lymphocyte count from the baseline
50% reduction in the sum of the products of the largest measured node or nodal masses on physical examination.
50% reduction in size of liver and/or spleen
50% improvement in neutrophils, platelets and hemoglobin</description>
          <population>All patients were evaluable for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="86" upper_limit="99"/>
                    <measurement group_id="O2" value="97" lower_limit="85" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depth of Response After Ofatumumab Consolidation</title>
        <description>The proportion of patients with an improvement in depth of response with the addition of ofatumumab consolidation after PCO induction will be estimated by the number of patients with improvement in response from the time of response evaluation at the completion of PCO to the time of response evaluation at the completion of ofatumumab consolidation divided by the total number of evaluable patients. The hierarchy for depth of response will be in the following increasing order: SD, PR, nPR, CR/CRi with MRD+, CR/CRi with MRD-. An improvement in depth of response will be defined as an improvement of at least one level in the hierarchy. Exact binomial 95% confidence intervals for the true overall improvement rate will be calculated.</description>
        <time_frame>14 months</time_frame>
        <population>Thirty-one out of the 34 patients registered to Arm B: PCO+O began consolidation, 28 were evaluated for response at the end of consolidation treatment (3 patients did not return for response evaluation at the end of treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: PCO</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: PCO +O</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.
For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Depth of Response After Ofatumumab Consolidation</title>
          <description>The proportion of patients with an improvement in depth of response with the addition of ofatumumab consolidation after PCO induction will be estimated by the number of patients with improvement in response from the time of response evaluation at the completion of PCO to the time of response evaluation at the completion of ofatumumab consolidation divided by the total number of evaluable patients. The hierarchy for depth of response will be in the following increasing order: SD, PR, nPR, CR/CRi with MRD+, CR/CRi with MRD-. An improvement in depth of response will be defined as an improvement of at least one level in the hierarchy. Exact binomial 95% confidence intervals for the true overall improvement rate will be calculated.</description>
          <population>Thirty-one out of the 34 patients registered to Arm B: PCO+O began consolidation, 28 were evaluated for response at the end of consolidation treatment (3 patients did not return for response evaluation at the end of treatment).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="25" lower_limit="11" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-free Survival</title>
        <description>Treatment-free survial is defined as the time from registration to the date of initiation of subsequent treatment for CLL or death due to any cause. The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier.</description>
        <time_frame>up to 5 years from registration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: PCO</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: PCO +O</title>
            <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.
For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-free Survival</title>
          <description>Treatment-free survial is defined as the time from registration to the date of initiation of subsequent treatment for CLL or death due to any cause. The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" lower_limit="50.16" upper_limit="NA">There have not been a sufficient number of events to calculate the upper 95% confidence limit.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="33.8" upper_limit="NA">There have not been a sufficient number of events to calculate the median and upper 95% confidence limit.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A: PCO</title>
          <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: PCO +O</title>
          <description>Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6.
During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.
For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mobitz (type) II atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="179" subjects_affected="40" subjects_at_risk="48"/>
                <counts group_id="E2" events="183" subjects_affected="32" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="18" subjects_at_risk="48"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="25" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="48"/>
                <counts group_id="E2" events="40" subjects_affected="19" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="118" subjects_affected="18" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="55" subjects_affected="23" subjects_at_risk="48"/>
                <counts group_id="E2" events="96" subjects_affected="26" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="205" subjects_affected="33" subjects_at_risk="48"/>
                <counts group_id="E2" events="248" subjects_affected="30" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="70" subjects_affected="27" subjects_at_risk="48"/>
                <counts group_id="E2" events="150" subjects_affected="28" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tait D. Shanafelt, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>shanafelt.tait@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

